Line 11: |
Line 11: |
| ! REFERENCES | | ! REFERENCES |
| |- | | |- |
− | | GLIOMAS | + | |'''GLIOMAS''' |
| | | | | |
| | | | | |
Line 206: |
Line 206: |
| |PMID:22832581; PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768 PMID:20940197 PMID:23175120 | | |PMID:22832581; PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768 PMID:20940197 PMID:23175120 |
| |- | | |- |
| + | |Atypical teratoid/rhabdoid tumor (AT/RT) |
| + | | |
| + | |'''Loss:''' 22/22q, though a subset of AT/RT-like tumors retain 22q |
| + | |Classic AT/RT: SMARCB1 mutation/deletion/exonic duplication in 98% of tumors<br> |
| + | AT/RT-like tumors: SMARCB1 can be retained (with SMARCA4 mutations)<br> |
| + | '''Three molecular classes:'''<br> |
| + | '''TYR:''' ~ 75% show broad 22q loss that includes SMARCB1<br> |
| + | '''SHH:''' ~ 50% lack any SMARCB1 mutation; ~ 25% have focal SMARCB1 aberrations<br> |
| + | '''MYC:''' ~ 75% show focal SMARCB1 loss |
| + | |Most cases occur before 3 yrs of age<br> |
| + | TYR subclass: mostly infratentorial<br> |
| + | SHH subclass: supra/infratentorial<br> |
| + | MYC subclass: mostly supratentorial |
| + | | |
| + | |- |
| + | |Embryonal tumor with multilayered rosettes, C19MC-altered |
| + | | |
| + | |'''ETMR (incl. ETANTR):''' occasionally polysomy 2 |
| + | |'''ETANTR:''' miRNA cluster C19MC amplification |
| + | |Occurs mainly in children < 4 yrs old |
| + | | WHO CNS Tumors (2016)<br> |
| + | PMID:24839957; PMID:24470553 PMID:24337497; PMID:22324795 PMID:20407781, PMID:19057917 |
| + | |- |
| + | |Embryonal tumor, other |
| + | | |
| + | |'''CNS NB-FOXR2 group:''' 1q gain, 16q loss, polysomy 8<br> |
| + | '''CNS EFT-CIC group:''' polysomy 8<br> |
| + | '''CNS HGNET-MN1 group:''' 16q loss, polysomy 8<br> |
| + | '''CNS HGNET-BCOR group:''' mostly balanced genomes |
| + | |'''CNS NB-FOXR2 group:''' JMJD1C fusions, FOXR2 fusion or deletion<br> |
| + | '''CNS EFT-CIC group:''' NUTM1 rearrangement/fusion, CIC rearrangement<br> |
| + | '''CNS HGNET-MN1 group:''' MN1 rearrangement <br> |
| + | '''CNS HGNET-BCOR group:''' BCOR intragenic tandem duplication |
| + | |Most common in children, but may also occur in adolescents and adults |
| + | |WHO CNS Tumors (2016)<br> |
| + | PMID:26919435; PMID:22691720; PMID:22772606 |
| + | |- |
| + | |'''CHOROID PLEXUS TUMORS (CPT)''' |
| + | |Choroid plexus papilloma(CPP, WHO grade I) and atypical choroid plexus papilloma (WHO grade II) |
| + | |'''Hyperdiploidy'''<br> |
| + | '''Loss:''' rare, no recurrent losses |
| + | |No diagnostic mutations/events |
| + | |CPP and aCPP likely belong to same molecularly defined entity; CPP is a diagnostic feature of Aircardi syndrome |
| + | |WHO CNS Tumors (2016)<br> |
| + | PMID:23172371; PMID:25575132; PMID:25336695 PMID:11891207 |
| + | |- |
| + | | |
| + | |Choroid plexus carcinoma (CPC, WHO grade III) |
| + | |'''Aneuploidy''' (including both hypo- and hyperdiploidy types of CPC); copy neutral LOH is frequent, particularly involving chromosome 17<br> |
| + | '''Gain:''' 1, 7, 12, 20 in > 80% of hyperdiploid CPCs<br> |
| + | '''Loss:''' 3 (in all hypodiploid CPC), 6, 11, 12q, 16, 22 |
| + | |'''Mutation:''' TP53 in > 50%<br> |
| + | '''Amplification:''' PDGFRB |
| + | |80% occur in children; associated with Li-Fraumeni syndrome; Lack of SMARCB1/SMARCA4 aberrations can be used to distinguish CPC from AT/RT |
| + | |PMID:24478045; PMID:21990040; PMID:25575132; PMID:18157090; PMID:25336695 |